TRUQAP 160MG/ 200MG TAB (CAPIVASERTIB)

🧬 Introduction & Composition

• Brand Name: Truqap

• Generic Name (Salt): Capivasertib 

• Drug Class: Oral AKT (serine/threonine) kinase inhibitor targeting the PI3K/AKT pathway

💊 Formulation & Strengths

• Dosage Forms: Film-coated tablets

• Available Strengths: 160 mg and 200 mg

📋 Indications

• Approved in November 2023 (US FDA; mid‑2024 EU) for HR-positive, HER2-negative advanced breast cancer in adults, used in combination with fulvestrant after progression on prior endocrine therapy

🧪 Dosing & Administration

• Recommended Regimen: 400 mg taken twice daily on Days 1–4, followed by 3 days off weekly (e.g., Monday–Thursday on, Friday–Sunday off)

• Administration: With or without food; swallow whole – do not crush or chew

• Missed Dose Guidance:

  • Less than 4 hours late: take promptly

  • More than 4 hours late: skip that dose; resume schedule

⚠️ Major Precautions & Drug Interactions

• Avoid grapefruit products and certain medications. Examples include ketoconazole, rifampin, verapamil, Paxlovid, etc.

• Monitoring: Regular blood sugar checks and manage hyperglycemia risks

🌡️ Side Effects

     Common

• Diarrhea (~77%)

• Nausea (around 35%)

• Stomatitis (mouth sores)

• Fatigue (~38%)

• Skin reactions (rash, hand-foot syndrome)

• Hyperglycemia (~19%)

• Renal injury (~11%)

• Headache, urinary tract infections, and more

     Serious or Dose-Limiting

• High blood sugar, risking diabetic ketoacidosis

• Severe diarrhea leading to dehydration

• Kidney impairment including acute injury

• Low blood cell counts (e.g., lymphocytes, neutrophils, platelets)

• Serious allergic or skin reactions

🔄 Management & Dose Modifications

• Diarrhea:

  • Grade 2: continue with supportive care

  • Grade 3: pause until ≤ Grade 1, then restart at reduced dose

  • Grade 4: permanently stop

• Skin Reactions:

  • Grade 1: topical treatments

  • Grade 2–3: hold drug until improvement; consider dose reduction

  • Grade 4: permanently discontinue

✅ Summary Conclusion

         Truqap (capivasertib) offers a novel oral therapy targeting the PI3K/AKT pathway for advanced HR+/HER2– breast cancer post-endocrine therapy.

         It follows a 4-days-on/3-days-off schedule and can be effective in combination with fulvestrant. However, it requires:

• Strict monitoring of gastrointestinal health, blood sugar, kidney function, and blood counts

• Proactive management of adverse effects (especially diarrhea, skin issues, hyperglycemia)

• Avoidance of interacting medications and grapefruit

• Diligent monitoring and patient education